Table 2.
Predicted essential genes and potential drug targets.
| ORF | Gene Symbol | EC | Enzyme | Evidence |
|---|---|---|---|---|
| a) Intersection of our predictions with the experimental screen | ||||
| STM0123 | murE | 6.3.2.13 | UDP-N-acetylmuramoylalanyl-D-glutamate-2,6-diaminopimelate ligase | ** |
| STM0128 | murG | 2.4.1.227 | N-acetylglucosaminyl transferase | * |
| STM0129 | murC | 6.3.2.8 | UDP-N-acetylmuramate-L-alanine ligase | ** |
| STM0154 | lpdA | 1.8.1.4 | Dihydrolipoamide dehydrogenase | |
| STM0218 | pyrH | 2.7.4.22 | Uridylate kinase | * |
| STM0221 | uppS | 2.5.1.31 | Undecaprenyl pyrophosphate synthase | ** |
| STM0222 | cdsA | 2.7.7.41 | CDP-diglyceride synthase | |
| STM0228 | lpxA | 2.3.1.129 | UDP-N-acetylglucosamine acyltransferase | |
| STM0232 | accA | 6.4.1.2 | Acetyl-CoA carboxylase | ** |
| STM0489 | hemH | 4.99.1.1 | Ferrochelatase | * |
| STM0535 | lpxH | UDP-2,3-diacylglucosamine hydrolase | ||
| STM0542 | folD | 1.5.1.5, 3.5.4.9 | Bifunctional 5,10-methylene-tetrahydrofolate dehydrogenase | |
| STM0988 | kdsB | 2.7.7.38 | CTP:CMP-KDO cytidylyltransferase | * |
| STM1194 | fabD | 2.3.1.39 | Acyl carrier protein S-malonyltransferase | * |
| STM1195 | fabG | 1.1.1.100 | 3-ketoacyl-(acyl-carrier-protein) reductase | ** |
| STM1200 | tmk | 2.7.4.9 | Thymidylate kinase | |
| STM1700 | fabI | 1.3.1.10 | Enoyl-(acyl carrier protein) reductase | |
| STM2483 | dapE | 3.5.1.18 | Succinyl-diaminopimelate desuccinylase | |
| STM2652 | pssA | 2.7.8.8 | Phosphatidylserine synthase | * |
| STM3090 | metK | 2.5.1.6 | ||
| STM3415 | rpoA | 2.7.7.6 | DNA-directed RNA polymerase subunit alpha | |
| STM3724 | kdtA | 3-deoxy-D-manno-octulosonic-acid transferase | * | |
| STM3730 | dfp | 4.1.1.36 | Pantothenate kinase | ** |
| STM3912 | rep | 3.6.1.- | ATP-dependent DNA helicase Rep | * |
| STM3978 | yigC | 3-octaprenyl-4-hydroxybenzoate decarboxylase | ||
| STM4153 | rpoB | 2.7.7.6 | DNA-directed RNA polymerase subunit beta | * |
| STM4154 | rpoC | 2.7.7.6 | DNA-directed RNA polymerase subunit beta' | |
| b) Predictions for the non-mevalonate pathway | ||||
| STM0049 | ispH, lytB | 1.17.1.2 | 4-hydroxy-3-methylbut-2-enyl diphosphate reductase | * |
| STM0220 | dxr | 1.1.1.267 | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | * |
| STM0422 | dxs | 2.2.1.7 | 1-deoxy-D-xylulose-5-phosphate synthase | ** |
| STM0423 | ispA | 2.5.1.10 | geranyltranstransferase | * |
| STM1779 | ispE, ipk | 2.7.1.149 | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase | ** |
| STM2523 | ispG, gcpE | 1.17.7.1 | 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase | * |
| STM2929 | ispF | 4.6.1.12 | 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase | * |
| STM2930 | ispD | 2.7.7.60 | 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase | * |
** clear evidence to be a drug target
* reasonable evidence to serve as a good drug target